Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00199264
Status:
TERMINATED
Last Update Posted:
2006-10-03
First Post:
2005-09-13
Brief Title:
Efficacy Vulvovaginitis Candida
Sponsor:
J Uriach and Company
Organization:
J Uriach and Company
Study Overview
Official Title:
A Single-Blind Randomized Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis
Status:
TERMINATED
Status Verified Date:
2003-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the therapeutic efficacy of 10 mg 40 mg 80 mg 160 mg and 320 mg of albaconazole as a single oral dose in women affected by acute non-complicated vulvovaginitis due to Candida spp
Detailed Description:
Multi-center open-label randomized study controlled with fluconazole
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None